Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects

Blood

Volumn 96, Issue 2, 2000, Pages 676-684

  Salomoni, Paolo ^b   Condorelli, Fabrizio ^b   Sweeney, Shawn M ^b   Calabretta, Bruno ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; INTERLEUKIN 3; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL X;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; DEPHOSPHORYLATION; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0034662158     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.2.676     Document Type: Article

References (44)

1. Clark SS, McLaughlin J, Timmonis M, et al. Expression of a distinctive bcr-abl oncogene in Ph1-positive acute lymphoblastic leukemia (ALL). Science. 1988;239:775-779.
2. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from bcr-abl fused gene. Cell. 1986;47:277-286.
3. Christopoulos C, Kottoris K, Mikraki V, Anevlavis E. Presence of the bcr/abl rearrangement in a patient with chronic neutrophilic leukaemia. J Clin Pathol. 1996;49:1013-1015.
4. Briz M, Vilches C, Cabrera R, Fores R, Fernandez M. Typical chronic myelogenous leukemia with e19a2 junction BCR/ABL transcript. Blood. 1997;90:5024-5025.
5. bcr/abl protein. Proc Natl Acad Sci U S A. 1988;85:9312-9316.
6. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-1088.
7. Gishizki ML, Witte ON. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science. 1992;256:836-839.
8. bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
9. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature. 1990;344:251-253.
10. Li S, Ilaria RL, Million RP, Daley GA, Van Etten RA. The p190, p210 and p230 forms of the BCR/ ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice, but have different lymphoid leukemogenic activity. J Exp Med. 1999;189:1399-1412.
11. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR/ABL in chronic myeloid leukemia. Blood. 1994;83:2038-2044.
12. Cortez D, Kadlec L, Pendergast AM. Structural and signalling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 1995;15:5531-5541.
13. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR/ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 1994;83:1179-1187.
14. Salomoni P, Wasik MA, Riedel RF, et al. Expression of constitutively active Raf-1 in the mitochondria restores anti-apoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J Exp Med. 1998;187:1995-2007.
15. Oltvai Z, Korsmeyer S. Checkpoints of dueling dimers foil death wishes. Cell. 1994;79:189-192.
16. Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci U S A. 1995;92:7834-7838.
17. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491-501.
18. Wang K, Yian X-M, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev. 1996;10:2859-2869.
19. 2, displaces Bax and promotes cell death. Cell. 1995;80:285-291.
20. L. Cell. 1996;87:619-628.
21. Puthalakath H, Huang DCS, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member BIM is regulated by interaction with the dynein motor complex. Mol Cell. 1999;3:287-296.
22. Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling molecules is mediated by the recognition of phosphoserine. Cell. 1996;84:889-897.
23. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.
24. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278:687-689.
25. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/ caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479-489.
26. Sanchez-Garcia I, Grötz G. Tumorigenic activity of the BCR/ABL oncogenes is mediated by Bcl-2. Proc Natl Acad Sci U S A. 1995;92:5287-5291.
27. Sanchez-Garcia I, Martin-Zanca D. Regulation of Bcl-2 gene expression by BCR/ABL is mediated by Ras. J Mol Biol. 1997;267:225-228.
28. Amarante-Mendes GP, Naekyung Kim C, Liu L, et al. Bcr-Abl exerts its anti-apoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 1998;91:1700-1705.
29. Valtieri M, Tweardy DJ, Caracciolo D, et al. Cytokine-dependent granulocytic differentiation: regulation of proliferative and differentiative responses in a murine progenitor cell line. J Immunol. 1987; 138:3829-3835.
30. YmerS, Tucker WQ, Sanderson CJ, Hapel AJ, Campbell HD, Young IG. Constitutive synthesis of interleukin-3 by leukemia cell line WEHI-3B is due to retroviral insertion near the gene. Nature. 1985;317:255-258.
31. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 1997;16:6151-6161.
32. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A. 1993;90:8392-8396.
33. Salomoni P, Perrotti D, Martinez R, Franceschi C, Calabretta B. Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb is associated with induction of BCL-2 expression and Myb-dependent regulation of bcl-2 promoter activity. Proc Natl Acad Sci U S A. 1997;96:3296-3301.
34. Cortez D, Stoica G, Pierce JH, Pendergast AM. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a RAS-dependent signaling pathway. Oncogene. 1996;13:2589-2594.
35. Villa-Moruzzi E, Della Zonca P, Crabb JW. Phosphorylation of the catalytic subunit of type-1 protein phosphatase by the v-abl tyrosine kinase. FEBS Lett. 1991;293:67-71.
36. Villa-Moruzzi E, Puntoni F. Phosphorylation of phosphatase-1α in cells expressing v-src. Biochem Biophys Res Commun. 1996;219:863-867.
37. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999;284:339-343.
38. Morana SJ, Wolf CM, Li J, Reynolds JE, Brown MK, Eastman A. The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis. J Biol Chem. 1996;271:18263-18271.
39. Dunigan DD, Madlener JC. Serine/threonine protein phosphatase is required for tobacco mosaic virus-mediated programmed cell death. Virology. 1995;207:460-466.
40. Mills JC, Lee VM, Pittman RN. Activation of a PP2A-like phosphatase and dephosphorylation of tau protein characterize onset of the execution phase of apoptosis. J Cell Sci. 1998;111:625-636.
41. Wolf CM, Eastman A. The temporal relationship between protein phosphatase, mitochondrial cytochrome c release, and caspase activation in apoptosis. Exp Cell Res. 1999;247:505-513.
42. Benito A, Lerga A, Silva M, Leon J, Fernandez-Luna JL. Apoptosis of human myeloid leukemia cells induced by an inhibitor of protein phosphatases (okadaic acid) is prevented by Bcl-2 and Bcl-X(L). Leukemia. 1997;11:940-944.
43. L by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Genes Dev. 1998;12:2475-2487.
44. Sanchez-Garcia I. Consequences of chromosomal abnormalities in tumor development. Annu Rev Genet. 1997;31:429-453.